A groundbreaking study conducted by the Innovation in Vesicles and Cells for Application in Therapy (IVECAT) group at the Germans Trias i Pujol Research Institute (IGTP) has unveiled a pivotal biochemical mechanism underpinning the anti-inflammatory capabilities of extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs). Published in the prestigious Journal of Extracellular Vesicles, this research significantly advances our understanding of the therapeutic potential of MSC-derived EVs in treating inflammatory pathologies and ischemic damage. The study elucidates the critical role of surface N-glycosylation in modulating the immunoregulatory ability of these nanoscale vesicles, offering fresh perspectives for bioengineering strategies targeting inflammatory diseases.
Mesenchymal stromal cells have long been a focal point of regenerative medicine due to their multipotent nature and immunomodulatory functions. Recently, extracellular vesicles secreted by these cells have garnered intense scientific interest for their capacity to mimic parent cell effects while bypassing some of the complexities associated with cell therapy. These vesicles, typically ranging from 30 to 150 nanometers, harbor a cargo of proteins, lipids, and nucleic acids capable of influencing recipient cell behavior. Leveraging their bioactive potential, MSC-derived EVs hold promise for nanoparticle-based interventions aimed at reducing endothelial inflammation following ischemic injury, a common precursor to atherosclerosis and organ failure.
The IVECAT research team has identified that N-glycosylation—a post-translational modification involving the attachment of oligosaccharide chains to asparagine residues on proteins and lipids—serves as a vital determinant of EV surface properties. This glycan decoration preserves the vesicles’ functional integrity, particularly their immunomodulatory effects. The study reveals that intact N-glycosylation is necessary for EVs to effectively inhibit monocyte recruitment to inflamed endothelial cells, a process intricately regulated via the MCP-1/CCR2 chemokine axis. Disruption of this glycosylation leads to diminished vesicle uptake and a compromised capacity to modulate monocyte-endothelial interactions under physiologically relevant shear flow conditions, emphasizing the biochemical specificity required for therapeutic efficacy.
To unravel these complex molecular interactions, the researchers innovatively employed an in vitro dynamic flow system replicating the hemodynamic forces encountered within the vascular microenvironment. This setup allowed for real-time observation of EV behavior and their interactions with inflamed endothelium and circulating monocytes, the primary immune cells orchestrating the initial inflammatory response. The model’s mimicry of physiological shear stress enabled the team to capture phenomena such as monocyte rolling and firm adhesion—critical precursors to extravasation—that are absent in traditional static culture methods. Consequently, this flow-based platform provided unparalleled insight into the kinetics and functional outcomes of EV-mediated immunomodulation.
Dr. Marta Clos-Sansalvador, co-first author of the study, highlights the transformative impact of integrating dynamic flow conditions into vesicle research. She emphasizes that this approach transcends conventional uptake assays by validating not only the internalization of EVs but also their downstream functional effects on immune cell recruitment and endothelial activation. Her colleague, Dr. Marta Monguió-Tortajada, adds that the ability of MSC-derived EVs to attenuate monocyte extravasation across inflamed endothelia sheds light on novel anti-inflammatory pathways that could be harnessed therapeutically.
The implications of these findings extend far beyond fundamental cell biology. The demonstration that surface glycosylation patterns critically dictate EV targeting and immune modulation opens avenues for the design of engineered vesicles with tailored glycan signatures. Such precision bioengineering could enhance vesicle specificity for inflamed vascular tissues and augment their therapeutic potency in conditions ranging from acute myocardial infarction to chronic inflammatory disorders. Furthermore, understanding the CCR2-driven recruitment mechanism offers a strategic target for pharmacological intervention, potentially improving patient outcomes by mitigating excessive monocyte infiltration and subsequent tissue damage.
The collaborative effort behind this study involved expertise from the IVECAT group, the microenvironment and metastasis group led by Dr. Héctor Peinado, and the advanced microscopy team at the Spanish National Cancer Research Centre (CNIO). This multidisciplinary integration enabled the deployment of cutting-edge imaging technologies, facilitating high-resolution visualization of vesicle-cell interactions and contributing to the comprehensive mechanistic elucidation presented. Additionally, mobility grants from the Spanish Group for Research and Innovation in Extracellular Vesicles (GEIVEX) played a crucial role in expanding access to specialized equipment and cross-institutional expertise, underscoring the importance of collaborative networks in driving scientific innovation.
Central to the translational potential of MSC-derived EVs is their ability to operate under dynamic vascular conditions, which this study robustly recapitulates. By systematically demonstrating that glycosylation state governs vesicle uptake and the suppression of monocyte recruitment via CCR2 pathways, the work provides a template for future therapeutics aimed at endothelial inflammation—a common denominator in numerous pathological states including stroke, peripheral artery disease, and diabetic vasculopathy.
Looking forward, the findings invite a re-examination of the molecular design principles governing extracellular vesicle function and targeting. Refinement of glycosylation patterns on EV surfaces could serve as a key lever to modulate biodistribution, cellular internalization, and payload delivery with unprecedented precision. This approach, combined with enhanced understanding of chemokine receptor signaling, has the potential to generate next-generation nanotherapeutics engineered to strategically intercept and resolve inflammation with minimal off-target effects.
Dr. Clos-Sansalvador succinctly encapsulates the transformative promise of this research: “Deciphering the glycosylation codes that regulate extracellular vesicle function is instrumental for the rational design of cell-free therapies with superior targeting abilities and therapeutic outcomes.” As the field of extracellular vesicle biology matures, integrating biochemical modifications with biomechanical understanding stands to revolutionize the therapeutic landscape for inflammatory and ischemic diseases worldwide.
This seminal study, titled “Surface N-Glycosylation Dictates MSC-EV Uptake and CCR2-Driven Monocyte Recruitment to Inflamed Endothelium Under Shear Flow,” not only advances fundamental scientific knowledge but also paves the way for innovative clinical applications. The comprehensive insights offered by the IVECAT group at IGTP represent a critical step toward realizing the full potential of mesenchymal stromal cell-derived extracellular vesicles as powerful, finely tuned agents of vascular immunomodulation.
Subject of Research: Cells
Article Title: Surface N-Glycosylation Dictates MSC-EV Uptake and CCR2-Driven Monocyte Recruitment to Inflamed Endothelium Under Shear Flow
News Publication Date: 28-May-2026
Web References: DOI: 10.1002/jev2.70316
Image Credits: IGTP
Keywords: Cell biology, Inflammation, Immunology, Cell therapies, Glycosylation, Extracellular matrix
